F10 and interstitial lung disease: However, it is unclear whether coprescribing of an FXa inhibitor with amiodarone and other specific drugs (eg, several cardiovascular, anti-inflammatory, antimicrobial, biological, or antitumor agents, which may induce ILD33) was associated with increased plasma levels of FXa inhibitor, amiodarone, and other specific drugs, leading to the vulnerability in the development of ILD during the long-term follow-up period.